A Phase 3 interventional study of Secukinumab in Lupus Nephritis, sponsored by Novartis Pharmaceuticals. Terminated at 18 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Lupus Nephritis by Novartis — 1 open to participants now, 3 under way, 2 of them phase 3. Lupus Nephritis · Novartis.
Among the 10 studies in Lupus Nephritis by Novartis, this one is one of 3 that started in 2022, is one of 4 in phase 3, and was the 6th registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →1 of the 10 studies in Lupus Nephritis by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, China and 15 more countries
Ages 18–100
By country, each count listing its studies:
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4
First in 2007; this study’s year is marked. 3 started in 2022.
This study's enrollment of 31 is below the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 81 across the 9 interventional studies, 69 across the 1 observational. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Lupus Nephritis by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Lupus Nephritis by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label extension study was to provide treatment with secukinumab for subjects who completed core study treatment in Study CAIN457Q12301 (NCT04181762), and to obtain further data on long-term efficacy, safety and tolerability of secukinunab in patients with active lupus nephritis (LN).
Investigators used their clinical judgement to decide if it might be beneficial, in terms of overall improvement and response to therapy, for subjects to enter the extension study. The planned total combined duration for the core study and this extension study was five years.
At Week 104 of the core study CAIN457Q12301, eligible subjects who completed the assessments associated with the core study visit subsequently continued in the extension study on the dose of secukinumab 300 mg administered every four weeks.
A total of 31 subjects were enrolled and received secukinumab 300 mg every four weeks until study termination. Recruitment in this study was stopped on 26-May-2023.
This study along with the core study (CAIN457Q12301) were terminated early by Novartis due to futile results of interim analysis 1 of the core study. There were no safety related reasons for early termination of either of the studies.
Key inclusion criteria:
Key Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Secukinumab 300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
Drug: Secukinumab
300 mg solution for subcutaneous (s.c.) injection in a 2mL Pre-Filled Syringe (PFS)
Also known as: AIN457
Percentage of Participants Achieving Complete Renal Response (CRR)
Complete Renal Response (CRR) is a composite endpoint defined as: * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of core Baseline values and * 24-hour Urine-to-Protein Creatinine Ratio (UPCR) =\< 0.5mg/mg The glomerular filtration rate was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on subject gender, age (years) and serum creatinine (mg/dL). Central laboratory serum creatinine values were used for all renal function data analysis. UPCR was determined by a central laboratory by dividing the protein concentration by the creatinine concentration as measured in the urine collected. UPCR was determined using one of the following two types of urine collection, 24-hour urine collection or first morning void urinary sample, both of which were collected in the subjects' home.
Time frame: Up to 28 weeks: from enrollment in the extension study (Week 104E1) up to Week 132 or Early termination of the Extension Study. Study day is defined with respect to the core study.
This study was conducted in 18 centers in 13 countries: Australia (1 site), Brazil (2 sites), Colombia (1 site), Czech Republic (2 sites), Guatemala (2 sites), Japan (2 sites), Korea (1 site), Republic of Philippines (1 site), Portugal (2 sites), Slovakia (Slovak Republic) (1 site), Spain (1 site), Thailand (1 site), Vietnam (1 site)
| Milestone | Secukinumab 300 mg | Placebo to Secukinumab 300 mg |
|---|---|---|
| Started | 16 | 15 |
| Completed | 0 | 0 |
| Not completed | 16 | 15 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Study terminated by sponsor | 16 | 14 |
Complete Renal Response (CRR) is a composite endpoint defined as: * Estimated Glomerular Filtration Rate (eGFR) \>= 60 mL/min/1.73 m\^2 or no less than 85% of core Baseline values and * 24-hour Urine-to-Protein Creatinine Ratio (UPCR) =\< 0.5mg/mg The glomerular filtration rate was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on subject gender, age (years) and serum creatinine (mg/dL). Central laboratory serum creatinine values were used for all renal function data analysis. UPCR was determined by a central laboratory by dividing the protein concentration by the creatinine concentration as measured in the urine collected. UPCR was determined using one of the following two types of urine collection, 24-hour urine collection or first morning void urinary sample, both of which were collected in the subjects' home.
| Participants | Secukinumab 300 mg | Placebo to Secukinumab 300 mg |
|---|---|---|
| Week 104E1 (Baseline Extension Study) (n = 9, 9) | 4 | 5 |
| Week 132 (n = 6, 5) | 3 | 5 |
Collected over On-treatment adverse events and deaths were reported from first dose of study treatment in the Core Study up to 84 days after last dose of study medication in the Extension Study, assessed up to approximately 3 year.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg | 0/16 (0%) | 4/16 (25%) | 15/16 (93.8%) |
| Placebo to Secukinumab 300 mg | 0/15 (0%) | 8/15 (53.3%) | 15/15 (100%) |
| Event | Secukinumab 300 mg | Placebo to Secukinumab 300 mg |
|---|---|---|
| COVID-19Infections and infestations | 0/16 | 2/15 |
| Urinary tract infectionInfections and infestations | 0/16 | 2/15 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/16 | 2/15 |
| DyspepsiaGastrointestinal disorders | 1/16 | 1/15 |
| Drug-induced liver injuryHepatobiliary disorders | 0/16 | 1/15 |
| Dengue feverInfections and infestations | 0/16 | 1/15 |
| EndometritisInfections and infestations | 0/16 | 1/15 |
| Pyelonephritis acuteInfections and infestations | 1/16 | 1/15 |
| Bipolar disorderPsychiatric disorders | 0/16 | 1/15 |
| Lupus nephritisRenal and urinary disorders | 0/16 | 1/15 |
| Event | Secukinumab 300 mg | Placebo to Secukinumab 300 mg |
|---|---|---|
| COVID-19Infections and infestations | 5/16 | 7/15 |
| Urinary tract infectionInfections and infestations | 4/16 | 5/15 |
| Herpes zosterInfections and infestations | 5/16 | 0/15 |
| DiarrhoeaGastrointestinal disorders | 2/16 | 4/15 |
| Upper respiratory tract infectionInfections and infestations | 0/16 | 4/15 |
| AnaemiaBlood and lymphatic system disorders | 4/16 | 3/15 |
| PharyngitisInfections and infestations | 0/16 | 3/15 |
| HypokalaemiaMetabolism and nutrition disorders | 1/16 | 3/15 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/16 | 3/15 |
| NauseaGastrointestinal disorders | 3/16 | 0/15 |
| Age, Continuous(Years) | Secukinumab 300 mg | Placebo to Secukinumab 300 mg | Total |
|---|---|---|---|
| Mean | 35.6 ± 8.26 | 30.6 ± 9.83 | 33.2 ± 9.26 |
| Age, Customized(Participants) | Secukinumab 300 mg | Placebo to Secukinumab 300 mg | Total |
|---|---|---|---|
| < 30 years | 4 | 7 | 11 |
| >= 30 years | 12 | 8 | 20 |
| Sex: Female, Male(Participants) | Secukinumab 300 mg | Placebo to Secukinumab 300 mg | Total |
|---|---|---|---|
| Female | 14 | 14 | 28 |
| Male | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Secukinumab 300 mg | Placebo to Secukinumab 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 0 | 6 |
| Asian | 8 | 8 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 2 | 6 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2022 to primary completion in Aug 2023, 12 months.
Results were first posted in Aug 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab